Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 74

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 74
---
. If we are unable to license or sublicense, sell or otherwise commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed.

Our business and the ability
to generate revenue related to product sales, if ever achieved, will depend on the successful development, regulatory approval and licensing
or sublicensing or other commercialization of our drug candidates or any other drug candidates we may develop. We have invested a significant
amount of financial resources in the development of our drug candidates and we may invest in other drug candidates. The success of our
drug candidates and any other potential drug candidates will depend on many factors, including but not limited to:

| ● | successful enrollment in, and completion of, studies in animals 
 and clinical trials;                                            |

| ● | other parties’ ability in conducting our clinical trials  
 safely, efficiently and according to the agreed protocol; |

| ● | receipt of regulatory approvals from the FDA, NMPA, EMA, Health             
 Canada and other comparable regulatory authorities for our drug candidates; |

| ● | our ability to establish commercial manufacturing capabilities 
 by making arrangements with third-party manufacturers;         |

| ● | reliance on other parties to conduct our clinical trials swiftly 
 and effectively;                                                 |

| ● | launch of commercial sales of our drug candidates, if and when 
 approved;                                                      |

| ● | obtaining and maintaining patents, trade secrets and other IP                          
 protection and regulatory exclusivity, as well as protecting our rights in our own IP; |

| ● | ensuring that we do not infringe, misappropriate or otherwise       
 violate patents, trade secrets or other IP rights of other parties; |

| ● | obtaining acceptance of our drug candidates by doctors and patients; |

| ● | obtaining reimbursement from third-party payors for our drug 
 candidates, if and when approved;                            |

| ● | our ability to compete with other drug candidates and drugs; 
 and                                                          |

| ● | maintenance of an acceptable safety profile for our drug candidates 
 following regulatory approval, if and when received.                |

We may not achieve regulatory
approval and commercialization in a timely manner or at all. Significant delays in obtaining approval for and/or to successfully commercialize
our drug candidates would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue
our operations.

Risks Related to Aptorum’s Intellectual Properties

A significant portion of our IP portfolio currently includes pending patent applications that have not yet been issued as granted patents and if the pending patent applications covering our